Solventum (SOLV) risk factors, FY2024 10-K

Risks Related to the Spin-Off and Solventum’s Relationship with 3M

1. 01Solventum’s historical financial information for periods prior to the Spin-Off is not necessarily representative of the results or performance that it would have achieved as a separate, publicly traded company and may not be a reliable indicator of its future results or performance
2. 02extensive global research and development resources, which historically enhanced its ability to innovate, develop new products and technologies, and improve and update existing products and technologies. Solventum’s lack of access to 3M’s research and development resources may negatively impact it
3. 03Solventum may not achieve some or all of the expected benefits of the Spin-Off
4. 04Solventum’s accounting and other management systems and resources may not be adequately prepared to meet the financial reporting and other requirements to which it is subject to as a standalone publicly traded company following the Spin-Off
5. 05In connection with the Spin-Off, Solventum incurred debt obligations and may incur additional obligations in the future, which could adversely affect its business and profitability and its ability to meet other obligations
6. 06Solventum may not be able to engage in desirable capital-raising or strategic transactions following the Spin-Off
7. 07Following the Spin-Off, Solventum’s commercial relationships with 3M remain significant, which could adversely affect Solventum’s business, its ability to meet other obligations and the market price of its common stock

General Economic and Business Risks

1. 08Solventum’s results may be impacted by the effects of, and changes in, worldwide economic, political, regulatory, international trade and geopolitical conditions, war and other events beyond its control
2. 09Public health crises such as the COVID-19 pandemic may increase Solventum’s cost of doing business and disrupt Solventum’s operations
3. 10Our brands are critical to our success, and damage to our reputation or our brands could adversely affect our business, results of operations or financial condition
4. 11Acquisitions, strategic alliances, divestitures and other strategic events resulting from portfolio management actions and other evolving business strategies, and possible further organizational restructuring, could affect future results
5. 12Solventum may not be able to access the capital and credit markets on terms that are favorable to Solventum, or at all
6. 13Change in Solventum’s credit ratings could increase cost of funding
7. 14Foreign currency exchange rates and fluctuations in those rates may affect Solventum’s ability to realize projected growth rates in its sales and earnings
8. 15Changes in interest rates could adversely affect Solventum

Market Dynamic Risks

1. 16Solventum operates in highly competitive markets, competition may increase in the future and the healthcare industry may be disrupted, necessitating that Solventum lower prices or resulting in a loss of market share
2. 17Consolidation in the healthcare industry could have an adverse effect on Solventum’s revenues and results of operations
3. 18Reductions in customers’ research budgets or government funding may adversely affect Solventum’s business
4. 19Solventum’s growth objectives are largely dependent on the timing and market acceptance of its new products and services, including its ability to continually renew its pipeline of new products and services and to bring those products and services to market
5. 20The success of many of Solventum’s products depends upon certain key healthcare professionals
6. 21Changes in reimbursement practices of third-party payers or other cost containment measures or worsening economic conditions could affect the demand for Solventum’s products and the prices at which they are sold
7. 223M is the sole source of supply for raw materials used in certain of our products and our business will be harmed if 3M does not satisfy our requirements

Legal and Compliance Risks

1. 23Solventum may face potential liabilities related to PFAS, which could adversely impact Solventum’s results
2. 24Climate change and the impacts of climate change may materially adversely affect Solventum’s business, results of operations, financial condition and cash flows
3. 25Solventum operates in a strictly regulated industry, and compliance with laws and regulations applicable to the commercialization of Solventum’s products is costly and failure to comply may result in significant penalties
4. 26Solventum is subject to laws and regulations governing government contracts, public procurement and government reimbursements in many jurisdictions, as to which the failure to comply could adversely affect Solventum’s business
5. 27Solventum is exposed to risks associated with product liability claims, including existing claims and claims resulting from the actions or inactions of its customers or third parties that are outside of its control
6. 28Information Technology and Intellectual Property Risks
7. 29Solventum may be unable to obtain, maintain, protect or effectively enforce its intellectual property rights
8. 30challenging or impossible. In addition, the laws of many jurisdictions may not provide an adequate forum to effectively address situations where Solventum’s intellectual property rights have been compromised

Tax Matters Risks

1. 31Changes in tax rates, laws or regulations could adversely impact Solventum’s financial results
2. 32Solventum’s tax burden could increase as a result of ongoing or future tax audits and inquiries
3. 33Solventum could be negatively impacted by future changes in the allocation of income to each of the income tax jurisdictions in which Solventum operates
4. 34If Solventum is unable to attract or retain key personnel and qualified employees, or maintain relations with its employees, unions and other employee representatives, Solventum’s business would be adversely affected

Risks Related to Solventum Common Stock

1. 35A significant number of shares of Solventum common stock may be sold by 3M or others, which may cause the Solventum stock price to decline
2. 36Because Solventum does not currently intend to pay any dividends on its common stock, holders of its common stock must rely on stock appreciation for any return on their investment. Solventum cannot guarantee the timing, declaration, amount or payment of dividends on its common stock
3. 37Anti-takeover provisions could enable Solventum’s Board of Directors to resist a takeover attempt by a third party and limit the power of its shareholders